Dietary supplement glutamine + standard therapy improved outcomes in advanced pancreatic cancer, Cedars-Sinai investigators find

Last month, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.